Application of acetylcorydalis in preparation of medicine for treating acute hepatic failure

By inhibiting the expression and phosphorylation of inflammatory factors and chemokines, the treatment problem of acute liver failure caused by intraperitoneal injection of D-galactose and lipopolysaccharides was solved, significantly improving liver function and preventing liver failure progress.

CN118903131APending Publication Date: 2024-11-08JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411257409.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is a lack of effective drugs in the prior art to treat acute liver failure caused by intraperitoneal injection of D-galactose combined with lipopolysaccharide, and the application of acetyl-virginine in this type of drug has not been studied.

Method used

By using acetyl-virginine, serum ALT, AST and IL-1β levels were reduced, mRNA expression of inflammatory factors TNF-α, IL-6, IL-1β, CCL3, CCL4, CCL5 and FOS in the liver, downregulating p65 and JNK Phosphorylated expression of proteins exerts an anti-inflammatory effect to treat acute liver failure.

Benefits of technology

Acetyl-virginine significantly reverses the mRNA expression levels of TNF-α, IL-6, IL-1β, CCL3, CCL4, CCL5, and FOS caused by LPS/D-GalN, reduces the phosphorylation of P65 and JNK, and alleviates liver failure. Improving liver function and preventing the development of acute liver failure provide an effective treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903131A_ABST
    Figure CN118903131A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of preparation of drugs for treating hepatic failure, in particular to application of acetylcorydalis in preparation of drugs for treating acute hepatic failure, acetylcorydalis can reduce the levels of ALT, AST and IL-1beta in serum, and the action mechanism of acetylcorydalis is that inflammatory factors TNF-alpha, IL-6 and IL-1beta in the liver and chemotactic factors CCL3, CCL4 and CCL5 in the liver and mRNA expression levels of FOS are inhibited, so that the acute hepatic failure can be inhibited. The medicine plays an anti-inflammatory role to treat hepatic failure; acetylcorydalis plays a role in resisting hepatic failure by inhibiting inflammation, and the action mechanism of acetylcorydalis is that the anti-inflammatory effect is played by down-regulating phosphorylation expression levels of p65 and JNK proteins, so that hepatic failure is resisted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of preparation of liver failure drugs, and in particular to application of acetyl corydaline in the preparation of drugs for treating acute liver failure. Background Art

[0002] Acute liver failure (ALF) is a massive necrosis of liver cells and severe liver function disorder caused by various reasons. It is characterized by rapid progression, severe deterioration and high mortality rate, bringing serious burden to patients and society.

[0003] Liver transplantation is the only way to treat liver failure, but it is extremely difficult to treat liver failure due to the shortage of liver sources, serious complications, immunosuppression, and high surgical costs.

[0004] Therefore, it is of great clinical significance to study the prevention and treatment of acute liver failure. Common modeling methods in experiments include D-galactosamine, lipopolysaccharide, acetaminophen, carbon tetrachloride, etc. Among them, the acute liver failure model induced by lipopolysaccharide combined with D-galactosamine can cause damage to the physiological function of the animal liver and be accompanied by a large amount of inflammation, and a large number of liver cells die in a short period of time. The modeling time is short, simple, and reproducible;

[0005] Acute liver failure is often closely related to inflammation, and macrophages play an important role. When liver failure and liver damage occur, macrophages play an important role in inflammation regulation and immune response. When the liver is damaged, macrophages are activated and release a variety of inflammatory mediators, such as tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), etc. These inflammatory mediators can cause inflammatory responses and recruit other immune cells into damaged areas, such as neutrophils and monocytes, thereby aggravating liver damage and the progression of liver failure. Therefore, regulating macrophages may become an important strategy for treating liver failure;

[0006] Natural products are the most common source of drugs. With the increasing research on them in recent years, more and more highly active compounds have been discovered, laying a certain foundation for the research and development of new drugs.

[0007] The present invention aims to find an effective drug for treating acute liver failure from natural products. Acetyl corydaline is a component extracted from the plant Corydalis of the genus Corydalis of the family Papaveraceae, which has anti-inflammatory and anti-inflammatory lung injury effects, and can also reduce the degeneration of dopaminergic neurons and the aggregation of a-synuclein in the animal model of Parkinson's disease;

[0008] There is currently only one literature report on the hepatoprotective activity of acetyl corydaline, entitled: Protective effects of corydaline, acetyl corydaline and protopyrine on experimental liver damage in mice (Wei Huailing, et al., Acta Pharmaceutica Sinica, 1997, 32(5), 331-336). This article describes that acetyl corydaline has a protective effect on experimental liver damage caused by CCl4, thioacetamide and paracetamol, and that acetyl corydaline has the ability to induce liver microsomal cytochrome P450, thereby exerting an anti-experimental liver damage effect.

[0009] So far, there is no information on the use of acetyl corydaline in the preparation of drugs for acute liver failure caused by intraperitoneal injection of D-galactosamine combined with lipopolysaccharide (D-GalN+LPS). Summary of the invention

[0010] The purpose of the present invention is to provide an application of acetyl corydaline in the preparation of a drug for treating acute liver failure. The technical problems solved by the present invention are:

[0011] Regarding the application of acetyl corydaline in the preparation of drugs for acute liver failure caused by intraperitoneal injection of D-galactosamine combined with lipopolysaccharide (D-GalN+LPS).

[0012] The purpose of the present invention can be achieved through the following technical solutions:

[0013] The application of acetyl corydaline is in the preparation of medicine for treating acute liver failure.

[0014] As a further solution of the present invention: Acetyl corydaline can reduce serum ALT, AST and IL-1β levels.

[0015] As a further embodiment of the present invention, acetyl corydaline can treat liver failure by inhibiting the mRNA expression levels of inflammatory factors TNF-α, IL-6, IL-1β and chemokines CCL3, CCL4, CCL5 and FOS in the liver, thereby exerting anti-inflammatory effects.

[0016] As a further solution of the present invention: Acetyl corydaline exerts anti-inflammatory effects by down-regulating the phosphorylation expression levels of p65 and JNK proteins, thereby resisting liver failure.

[0017] As a further embodiment of the present invention, acetyl corydaline exerts an anti-inflammatory effect by inhibiting the expression levels of mRNA of TNF-α, CCL3, CCL4, CCL5 and FOS in mouse macrophages RAW264.3.

[0018] As a further solution of the present invention: Acetyl corydaline exerts anti-inflammatory effects by down-regulating the phosphorylation expression levels of p65 and JNK proteins in mouse macrophages RAW264.3.

[0019] As a further solution of the present invention: the chemical structural formula of acetyl corydaline is as follows:

[0020]

[0021] As a further solution of the present invention: a drug for treating acute liver failure is prepared containing an effective amount of acetyl corydaline, a carrier, an additive and / or an excipient.

[0022] Beneficial effects of the present invention:

[0023] (1) In the present invention, in the mouse acute liver failure model caused by intraperitoneal injection of D-galactosamine combined with lipopolysaccharide (D-GalN+LPS) treated with acetyl corydaline, the expression levels of ALT, AST and IL-1β in serum were detected, and the pathological morphological changes of the liver were observed. Then, the mRNA expression levels of key genes in the Toll-like receptor signaling pathway in liver tissue were tested by RT-qPCR. The results showed that in the Toll-like receptor signaling pathway, acetyl corydaline can significantly reverse the upregulation of mRNA expression levels of TNF-α, IL-6, IL-1β, CCL3, CCL4, CCL5, and FOS caused by LPS / D-GalN. Western blot was further used to detect the phosphorylation levels of proteins P65 and JNK. The results showed that acetyl corydaline can reduce the phosphorylation levels of P65 and JNK. Therefore, acetyl corydaline alleviates LPS / D-GalN-induced liver failure in mice mainly by inhibiting the activation of Toll-like receptor signaling pathways, interfering with the expression of related inflammatory factors and chemokines, and reducing their secretion levels;

[0024] (2) The present invention studied the molecular mechanism of the anti-inflammatory effect of acetyl corydaline on LPS-stimulated mouse RAW 264.7 macrophages at the cellular level; RT-qPCR was used to test the mRNA expression levels of key genes in the Toll-like receptor signaling pathway in macrophages. Western blot was further used to analyze the phosphorylation levels of P65 and JNK proteins downstream of inflammation;

[0025] (3) The present invention evaluates the activity of the compound acetylcorynoline in treating acute liver failure and finds that the compound can improve liver function and reduce the secretion of inflammatory factors, effectively prevent the development of acute liver failure, and can be used as a drug for treating acute liver failure. Acetylcorynoline can be used as an active ingredient and combined with pharmaceutically acceptable carriers, additives and / or excipients to prepare a pharmaceutical preparation for treating acute liver failure. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The present invention will be further described below in conjunction with the accompanying drawings.

[0027] Figure 1 This is the HPLC chart of acetyl corydaline used in the present invention, mobile phase: acetonitrile and 0.05% ammonia solution, the ratio of acetonitrile and 0.05% ammonia solution is 70:30, column temperature is 30 degrees Celsius, flow rate is 1 mL / min, C18 chromatographic column;

[0028] Figure 2 is a figure in Example 1 of the present invention, showing the effect of acetyl corydaline on the levels of ALT, AST and IL-1β in the serum of mice induced by LPS / D-Gal N;

[0029] Figure 3 is a figure in Example 1 of the present invention, showing the effect of acetyl corydaline on the liver morphology of mice induced by LPS / D-Gal N;

[0030] Figure 4 is a figure in Example 1 of the present invention, which shows the effect of acetyl corydaline on the transcriptional levels of TNF-α, IL-6, IL-1β, CCL3, CCL4, CCL5 and FOS in the liver of mice induced by LPS / D-Gal N;

[0031] Figure 5 Figure 1 of Example 1 of the present invention, the effect of acetyl corydaline on LPS / D-Gal N-induced mouse protein expression;

[0032] Figure 6 is a figure in Example 2 of the present invention, which shows the effect of acetyl corydaline on the transcription levels of TNF-α, CCL3, CCL4, CCL5 and FOS in LPS-induced RAW264.7 macrophages;

[0033] Figure 7 Figure 2 of Example 2 of the present invention, the effect of acetyl corydaline on LPS-induced protein expression in RAW264.7 cells;

[0034] Figure 8 Experimental flow chart of the present invention. DETAILED DESCRIPTION

[0035] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] Example 1

[0037] See also Figure 8As shown, the effect of acetyl corynoline (AC) on acute liver failure induced by LPS / D-Gal N in mice

[0038] (I) Animal grouping and drug administration

[0039] Thirty-five C57BL / 6J male mice, weighing (19 g), were randomly divided into a blank group (Con), a model group (LPS / D-Ga lN), a control group (AC), a drug group (LPS / D-Ga l N+AC), and a positive drug group (Y), with 7 mice in each group. The drug group and the control group were intraperitoneally injected with 5 mg / kg acetyl corydaline solution for 3 days, the blank group and the model group were intraperitoneally injected with an equal dose of normal saline, and the positive drug group was intraperitoneally gavaged with 200 mg / kg bifendate solution for 7 days. One hour after the last day of drug administration, the model group, the drug group, and the positive drug group were intraperitoneally injected with 50 ug / kg LPS+500 mg / kg D-Ga l N mixed solution. LPS (L2630) was purchased from Sigma-Aldrich, D-galactosamine hydrochloride (S11019) was purchased from Yuanye Biotechnology Co., Ltd., and acetyl corydaline (HA060802) was purchased from Baoji Chenguang Biotechnology Co., Ltd., with a purity of more than 98%. Figure 1 .

[0040] (II) Effects of acetyl corydaline on ALT, AST and IL-1β in serum of mice induced by LPS / D-Gal N

[0041] The changes of ALT, AST and IL-1β in mouse serum were detected. Figure 2 . Compared with the blank group, the serum ALT, AST and IL-1β levels of mice in the model group were significantly increased, indicating that LPS / D-Ga l N induced liver function damage in mice and the model was successful; and there was no significant difference between the acetyl corydaline control group and the blank group, indicating that no liver toxicity would be produced at a dose of 5 mg / kg. The serum ALT, AST and IL-1β levels of mice in the drug group (LPS / D-Ga l N+AC) and the positive drug group (Y) were significantly reduced, and the difference was statistically significant, indicating that both acetyl corydaline and the positive drug have a good effect on improving liver function, and the effect of acetyl corydaline is equivalent to that of the positive drug.

[0042] (III) Effects of acetyl corydaline on pathological changes of mouse liver tissue induced by LPS / D-Gal N

[0043] The pathological morphology of liver tissues of mice in each group is shown in Figure 3As shown. The liver cell structure and morphology of mice in the blank group and the control group were normal, with complete central veins, clear liver lobule structure, and large and clear cell nuclei. No pathological damage was found in the control group, with complete cell morphology and structure, indicating that the intraperitoneal dose of 5 mg / kg of acetyl corydaline was within the safe range and was not toxic. Compared with the blank group, mice in the model group showed obvious pathological damage, hepatocyte necrosis, destruction of the liver lobule structure, a large number of inflammatory cells infiltrated in the portal area, and blurred boundaries of hepatocytes that were difficult to distinguish. After treatment in the drug-treated group and the positive drug group, the liver tissue improved significantly and the inflammatory cells decreased.

[0044] (IV) RT-qPCR-based study on the effect of acetyl corydaline on the expression of genes related to liver failure in mice induced by LPS / D-Gal N

[0045] The results are as follows Figure 4 As shown in the results, compared with the blank group, the expression levels of genes such as TNF-α, IL-6, IL-1β, CCL3, CCL4, CCL5, and FOS in the liver of the model group were significantly increased, and the administration of acetyl corydaline could significantly downregulate these genes. This indicates that acetyl corydaline plays an anti-liver failure role by participating in the Toll-like receptor signaling pathway.

[0046] (V) Western blot technique was used to detect the effect of acetyl corydaline on the expression of proteins related to liver failure induced by LPS / D-Gal N in mice

[0047] Western blotting showed that the protein phosphorylation levels in the model group were significantly higher than those in the blank group. Compared with the model group, the protein phosphorylation level in the acetyl corydaline group was significantly reduced. Figure 5 As shown in the results, LPS can also activate the c-Jun N-terminal kinase (JNK) pathway through TLR4, upregulate the phosphorylation level of JNK, and participate in regulating the release of inflammation-related cytokines. By detecting the phosphorylation levels of NF-κB and JNK, it was found that acetyl corydaline can inhibit the activation of NF-κB and JNK pathways in acute liver injury induced by LPS / D-Gal N in mice, thereby alleviating liver failure.

[0048] Example 2

[0049] See also Figure 8 As shown in Figure 2, the anti-inflammatory mechanism of acetyl corydaline on LPS-induced mouse RAW264.7 cells

[0050] Acetyl corydaline exerts its anti-liver failure effect through anti-inflammatory effect, and its anti-inflammatory effect on mouse RAW264.7 cells was further studied.

[0051] (I) Cell culture, passaging, CCK-8 assay for cell viability, and ELISA assay for IL-1β content in cell supernatant

[0052] Cell culture, passaging, CCK-8 method to detect cell viability and ELISA method to detect the content of IL-1β in cell supernatant refer to the literature (Qinning Li, et al. An integrated RNA-Seq and network pharmacology approach for exploring the preventive effect of Corydalis bungeana Turcz. Extract and Acety l corynoline on LPS-induced acute lung injury, Journal of Ethnopharmacogy 318, 2024, 117048);

[0053] (II) RT-qPCR-based study on the effects of acetyl corydaline on the mRNA levels of TNF-α, CCL3, CCL4, CCL5, FOS and other genes in LPS-induced RAW264.7

[0054] Based on the results of in vivo RT-qPCR experiments, the results were verified at the cellular level. Figure 6 As shown, acetyl corydaline can effectively reduce the elevated mRNA levels of TNF-α, CCL3, CCL4, CCL5, FOS and other genes in RAW264.7 cells caused by LPS stimulation, and the effect is more obvious with the increase of the administration concentration.

[0055] (III) Western blotting to study the effect of acetyl corydaline on LPS-induced RAW264.7 cell action proteins

[0056] Consistent with the in vivo experiments in mice, the phosphorylation levels of P65 and JNK were detected in RAW264.7 cells. Figure 7 As shown in the figure, the phosphorylation level of model group protein was significantly higher than that of blank group. After administration of acetyl corydaline, the phosphorylation levels of P65 and JNK gradually decreased with the increase of administration concentration, and the effect was significant at 20μM.

[0057] The above is a detailed description of an embodiment of the present invention, but the content is only a preferred embodiment of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.

Claims

1. Application of acetyl corydaline, It is characterized in that The application is in the preparation of medicines for treating acute liver failure.

2. The use of acetyl corydaline according to claim 1, It is characterized in that Acetylcorydaline can reduce serum ALT, AST and IL-1β levels.

3. The use of acetyl corydaline according to claim 1, It is characterized in that Acetyl corydaline can treat liver failure by inhibiting the mRNA expression levels of inflammatory factors TNF-α, IL-6, IL-1β and chemokines CCL3, CCL4, CCL5 and FOS in the liver, exerting anti-inflammatory effects.

4. The use of acetyl corydaline according to claim 1, It is characterized in that Acetylcorydaline exerts anti-inflammatory effects by downregulating the phosphorylation expression levels of p65 and JNK proteins, thereby preventing liver failure.

5. The use of acetyl corydaline according to claim 1, It is characterized in that The chemical structure of acetyl corydaline is as follows:

6. The use of acetyl corydaline according to claim 1, It is characterized in that The preparation method of the drug for treating acute liver failure contains an effective amount of acetyl corydaline, a carrier, an additive and / or an excipient.